Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs

Documenti analoghi

• Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
  di: Paola Guglielmelli, et al.
  Pubblicazione: (2026)
• Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
  Pubblicazione: (2025)
• Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems
  di: Yu‐Sung Chang, et al.
  Pubblicazione: (2025)
• Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib
  di: A. Laganà, et al.
  Pubblicazione: (2025)
• Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial
  di: Paula de Melo Campos, et al.
  Pubblicazione: (2025)